(-0.58%) 5 022.21 points
(-0.12%) 37 753 points
(-1.15%) 15 683 points
(0.21%) $82.86
(1.64%) $1.740
(-0.04%) $2 387.50
(0.05%) $28.42
(-0.45%) $949.90
(-0.03%) $0.937
(-0.12%) $10.98
(-0.09%) $0.802
(0.00%) $94.06
-1.01% SEK 255.80
Live Chart Being Loaded With Signals
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally...
Stats | |
---|---|
Today's Volume | 221 973 |
Average Volume | 535 246 |
Market Cap | 86.91B |
EPS | SEK0 ( 2024-02-07 ) |
Next earnings date | ( SEK2.16 ) 2024-04-24 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | 34.61 |
ATR14 | SEK0.161 (0.06%) |
Volume Correlation
Swedish Orphan Biovitrum Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Swedish Orphan Biovitrum Correlation - Currency/Commodity
Swedish Orphan Biovitrum Financials
Annual | 2023 |
Revenue: | SEK22.12B |
Gross Profit: | SEK14.05B (63.52 %) |
EPS: | SEK7.47 |
Q4 | 2023 |
Revenue: | SEK6.84B |
Gross Profit: | SEK4.46B (65.15 %) |
EPS: | SEK3.02 |
Q3 | 2023 |
Revenue: | SEK5.17B |
Gross Profit: | SEK4.00B (77.40 %) |
EPS: | SEK0.300 |
Q2 | 2023 |
Revenue: | SEK4.87B |
Gross Profit: | SEK3.50B (71.84 %) |
EPS: | SEK0.710 |
Financial Reports:
No articles found.
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators